Delayed Immune-related Sclerosing Cholangitis After Discontinuation of Pembrolizumab: A Case Report

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2022 Sep 26

PMID 36161046

Authors

Takeshi Tanaka

Arata Sakai

Masahiro Tsujimae

Yasutaka Yamada

Takashi Kobayashi

Atsuhiro Masuda

Yuzo Kodama

Affiliations

Soon will be listed here.

Abstract

Background: Secondary sclerosing cholangitis, characterized by biliary obstruction, can be caused by drugs such as immune checkpoint inhibitors (ICIs). While there a few reports of sclerosing cholangitis after immune checkpoint inhibitor administration, no case has been reported after discontinuation of such drugs.

Case Summary: A 68-year-old man who underwent chemotherapy for lung adenocarcinoma with bone metastasis presented with abdominal pain and fever 4 mo after the final administration of pembrolizumab. Computed tomography revealed thickening of the gallbladder wall and dilatation of the common bile duct. Endoscopic retro-grade cholangiopancreatography revealed an irregularly narrowed intrahepatic bile duct. Biopsy of the bile duct demonstrated that CD8 T cells were predominant over CD4 T cells. Liver biopsy showed dominant infiltration of CD8 T in the portal tract, but onion-skin lesions were not observed. The patient was diagnosed with immune-related sclerosing cholangitis induced by pembrolizumab. Administration of methylprednisolone and endoscopic nasobiliary drainage were performed, but the cholangiography and laboratory test findings did not improve. No further treatment was administered due to disease progression, and the patient was referred for palliative care.

Conclusion: Immune-related sclerosing cholangitis may have a late onset, and such cases occurring after discontinuation of ICIs should be carefully managed.

Citing Articles

Etiology and Clinical Features of Secondary Sclerosing Cholangitis: A Single-Center Retrospective Study From 2016 to 2024.

Meng X, Peng J, Wei H JGH Open. 2025; 9(2):e70122.

PMID: 39989845 PMC: 11845274. DOI: 10.1002/jgh3.70122.

Immune-Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges.

Dara L, De Martin E Liver Int. 2025; 45(2):e16198.

PMID: 39868913 PMC: 11771569. DOI: 10.1111/liv.16198.

Delayed onset autoimmune cholangitis in a patient treated with pembrolizumab.

Newington J, Patterson D, Sanchez P BJR Case Rep. 2024; 10(6):uaae040.

PMID: 39512511 PMC: 11543344. DOI: 10.1093/bjrcr/uaae040.

Successful replacement for recurrent nasopharyngeal carcinoma with cholecystitis induced by PD-1 antibody: a case report.

Liu Z, Du X, Deng M, Chen Y, Wu S Immunotherapy. 2024; 16(14-15):949-953.

PMID: 39229795 PMC: 11485857. DOI: 10.1080/1750743X.2024.2382670.

Clinical features, treatment, and outcome of pembrolizumab induced cholangitis.

Fang W, Sun W, Fang W, Zhang J, Wang C Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(10):7905-7912.

PMID: 38748225 DOI: 10.1007/s00210-024-03135-2.

References

Zhu G, Shi K, Huang G, Wang L, Lin Y, Braddock M . A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis. Oncotarget. 2015; 6(29):26757-69. PMC: 4694950. DOI: 10.18632/oncotarget.5610. View

Weber J, Yang J, Atkins M, Disis M . Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015; 33(18):2092-9. PMC: 4881375. DOI: 10.1200/JCO.2014.60.0379. View

Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M . Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs. 2017; 35(4):529-536. DOI: 10.1007/s10637-017-0453-0. View

Visentin M, Lenggenhager D, Gai Z, Kullak-Ublick G . Drug-induced bile duct injury. Biochim Biophys Acta Mol Basis Dis. 2017; 1864(4 Pt B):1498-1506. DOI: 10.1016/j.bbadis.2017.08.033. View

Brooling J, Leal R . Secondary Sclerosing Cholangitis: a Review of Recent Literature. Curr Gastroenterol Rep. 2017; 19(9):44. DOI: 10.1007/s11894-017-0583-8. View

Couey M, Bell R, Patel A, Romba M, Crittenden M, Curti B . Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer. 2019; 7(1):165. PMC: 6609357. DOI: 10.1186/s40425-019-0645-6. View

Kashima J, Okuma Y, Shimizuguchi R, Chiba K . Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother. 2017; 67(1):61-65. PMC: 11028312. DOI: 10.1007/s00262-017-2062-3. View

Puzanov I, Diab A, Abdallah K, Bingham 3rd C, Brogdon C, Dadu R . Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017; 5(1):95. PMC: 5697162. DOI: 10.1186/s40425-017-0300-z. View

Khoja L, Day D, Wei-Wu Chen T, Siu L, Hansen A . Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017; 28(10):2377-2385. DOI: 10.1093/annonc/mdx286. View

10.

Sandrasegaran K, Alazmi W, Tann M, Fogel E, McHenry L, Lehman G . Chemotherapy-induced sclerosing cholangitis. Clin Radiol. 2006; 61(8):670-8. DOI: 10.1016/j.crad.2006.02.013. View

11.

Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T . Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018; 3(19). PMC: 6237460. DOI: 10.1172/jci.insight.59125. View

12.

Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H . Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol. 2020; 26(3):353-365. PMC: 6969883. DOI: 10.3748/wjg.v26.i3.353. View

13.

de La Rochefoucauld J, Noel N, Lambotte O . Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach. Intern Emerg Med. 2020; 15(4):587-598. DOI: 10.1007/s11739-020-02295-2. View

14.

Hofmann L, Forschner A, Loquai C, Goldinger S, Zimmer L, Ugurel S . Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016; 60:190-209. DOI: 10.1016/j.ejca.2016.02.025. View

15.

Kanaoka K, Moriizumi K, Okada H, Iwahashi K, Tsuji H, Yasuoka H . Pembrolizumab-Induced Delayed-Onset Hepatitis. Case Rep Gastroenterol. 2020; 14(3):586-592. PMC: 7670324. DOI: 10.1159/000509953. View

16.

Koya Y, Shibata M, Shinohara N, Nebuya S, Oe S, Honma Y . Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: Case report and review of published work. Hepatol Res. 2019; 49(8):950-956. DOI: 10.1111/hepr.13329. View